［1］ SHAPIRO J,VAN LANSCHOT JJB,HULSHOF M,et al.Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (cross):Long-term results of a randomised controlled trial ［J］.The Lancet Oncology,2015,16(9):1090-1098.
［2］ EYCK BM,VAN LANSCHOT JJB,HULSHOF M.Ten-year outcome of neoadjuvant chemoradiotherapy plus surgery for esophageal cancer:The randomized controlled cross trial ［J］.J Chin Oncol,2021,39(18):1995-2004.
［3］ YANG H,LIU H,CHEN Y,et al.Long-term efficacy of neoadjuvant chemoradiotherapy plus surgery for the treatment of locally advanced esophageal squamous cell carcinoma:The neocrtec5010 randomized clinical trial ［J］.JAMA surgery,2021,156(8):721-729.
［4］ ZHUO ZG,ZHU YK,DENG HY,et al.Predictive value of excision repair cross-complementation group 1 in the response to platinum-based chemotherapy in esophageal cancer:A meta-analysis ［J］.Oncology Research and Treatment,2020,43(4):160-169.
［5］ RUMIATO E,CAVALLIN F,BOLDRIN E,et al.Ercc1 c8092a (rs3212986) polymorphism as a predictive marker in esophageal cancer patients treated with cisplatin/5-Fu-based neoadjuvant therapy ［J］.Pharmacogenetics and Genomics,2013,23(11):597-604.
［6］ IQBAL S,MCDONOUGH S,LENZ HJ,et al.Randomized,phase II study prospectively evaluating treatment of metastatic esophageal,gastric,or gastroesophageal cancer by gene expression of ercc1:Swog s1201 ［J］.Journal of Clinical Oncology,2020,38(5):472-479.
［7］ ZHANG Y,DONG S,XU R,et al.Prognostic and predictive role of cox-2,xrcc1 and rassf1 expression in patients with esophageal squamous cell carcinoma receiving radiotherapy ［J］.Oncology Letters,2017,13(4):2549-2556.
［8］ BRABENDER J,METZGER R,VALLBOHMER D,et al.Roles of thymidylate synthase and dihydropyrimidine dehydrogenase expression in blood as predictors of response to multimodal therapy in esophageal cancer ［J］.Surgery,2012,151(2):306-312.
［9］ OKUMURA H,UCHIKADO Y,OMOTO I,et al.Ferredoxin reductase is useful for predicting the effect of chemoradiation therapy on esophageal squamous cell carcinoma ［J］.Anticancer Research,2015,35(12):6471-6474.
［10］ ZHANG J,JIAO Q,KONG L,et al.Nrf2 and keap1 abnormalities in esophageal squamous cell carcinoma and association with the effect of chemoradiotherapy ［J］.Thoracic Cancer,2018,9(6):726-735.
［11］ KAWASAKI Y,OKUMURA H,UCHIKADO Y,et al.Nrf2 is useful for predicting the effect of chemoradiation therapy on esophageal squamous cell carcinoma ［J］.Annals of Surgical Oncology,2014,21(7):2347-2352.
［12］ LI L,SUN J,LIU N,et al.Clinical outcome-related cancer pathways and mutational signatures in patients with unresectable esophageal squamous cell carcinoma treated with chemoradiotherapy ［J］.International Journal of Radiation Oncology,Biology,Physics,2022,24(6):1014-1032.
［13］ KIMURA T,SUZUKI K.Components of the electron transport system in adrenal steroid hydroxylase.Isolation and properties of non-heme iron protein (adrenodoxin) ［J］.The Journal of Biological Chemistry,1967,242(3):485-491.
［14］ HWANG PM,BUNZ F,YU J,et al.Ferredoxin reductase affects p53-dependent,5-fluorouracil-induced apoptosis in colorectal cancer cells ［J］.Nature Medicine,2001,7(10):1111-1117.
［15］ LIU G,CHEN X.The ferredoxin reductase gene is regulated by the p53 family and sensitizes cells to oxidative stress-induced apoptosis ［J］.Oncogene,2002,21(47):7195-7204.
［16］ TRAPASSO F,PICHIORRI F,GASPARI M,et al.Fhit interaction with ferredoxin reductase triggers generation of reactive oxygen species and apoptosis of cancer cells ［J］.The Journal of Biological Chemistry,2017,292(34):14279.
［17］ PICHIORRI F,OKUMURA H,NAKAMURA T,et al.Correlation of fragile histidine triad (fhit) protein structural features with effector interactions and biological functions ［J］.The Journal of Biological Chemistry,2009,284(2):1040-1049.
［18］ SHIBATA T,SAITO S,KOKUBU A,et al.Global downstream pathway analysis reveals a dependence of oncogenic nf-e2-related factor 2 mutation on the mtor growth signaling pathway ［J］.Cancer Research,2010,70(22):9095-9105.
［19］ JARAMILLO MC,ZHANG DD.The emerging role of the nrf2-keap1 signaling pathway in cancer ［J］.Genes & Development,2013,27(20):2179-2191.
［20］ VENUGOPAL R,JAISWAL AK.Nrf1 and nrf2 positively and c-fos and fra1 negatively regulate the human antioxidant response element-mediated expression of nad(p)h:Quinone oxidoreductase1 gene ［J］.Proceedings of the National Academy of Sciences of the United States of America,1996,93(25):14960-14965.
［21］ ISHII T,ITOH K,TAKAHASHI S,et al.Transcription factor nrf2 coordinately regulates a group of oxidative stress-inducible genes in macrophages ［J］.The Journal of Biological Chemistry,2000,275(21):16023-16029.
［22］ KATOH Y,ITOH K,YOSHIDA E,et al.Two domains of nrf2 cooperatively bind cbp,a creb binding protein,and synergistically activate transcription ［J］.Genes to Cells :Devoted to Molecular & Cellular Mechanisms,2001,6(10):857-868.
［23］ BANNING A,DEUBEL S,KLUTH D,et al.The gi-gpx gene is a target for nrf2 ［J］.Molecular and Cellular Biology,2005,25(12):4914-4923.
［24］ CHO HY,REDDY SP,KLEEBERGER SR.Nrf2 defends the lung from oxidative stress ［J］.Antioxidants & Redox Signaling,2006,8(1-2):76-87.
［25］ KENSLER TW,WAKABAYASHI N,BISWAL S.Cell survival responses to environmental stresses via the keap1-nrf2-are pathway ［J］.Annual Review of Pharmacology and Toxicology,2007,47:89-116.
［26］ STACY DR,ELY K,MASSION PP,et al.Increased expression of nuclear factor e2 p45-related factor 2 (nrf2) in head and neck squamous cell carcinomas ［J］.Head & Neck,2006,28(9):813-818.
［27］ CHO JM,MANANDHAR S,LEE HR,et al.Role of the nrf2-antioxidant system in cytotoxicity mediated by anticancer cisplatin:Implication to cancer cell resistance ［J］.Cancer Letters,2008,260(1-2):96-108.
［28］ LI W,KONG AN.Molecular mechanisms of nrf2-mediated antioxidant response ［J］.Molecular Carcinogenesis,2009,48(2):91-104.
［29］ ZHANG P,SINGH A,YEGNASUBRAMANIAN S,et al.Loss of kelch-like ech-associated protein 1 function in prostate cancer cells causes chemoresistance and radioresistance and promotes tumor growth ［J］.Molecular Cancer Therapeutics,2010,9(2):336-346.
［30］ MA X,ZHANG J,LIU S,et al.Nrf2 knockdown by shrna inhibits tumor growth and increases efficacy of chemotherapy in cervical cancer ［J］.Cancer Chemotherapy and Pharmacology,2012,69(2):485-494.
［31］ YANG H,WANG W,ZHANG Y,et al.The role of nf-e2-related factor 2 in predicting chemoresistance and prognosis in advanced non-small-cell lung cancer ［J］.Clinical Lung Cancer,2011,12(3):166-171.
［32］ FINDLAY JM,BRADLEY KM,WANG LM,et al.Predicting pathologic response of esophageal cancer to neoadjuvant chemotherapy:The implications of metabolic nodal response for personalized therapy ［J］.Journal of Nuclear Medicine,2017,58(2):266-275.
［33］ BECKER K,LANGER R,REIM D,et al.Significance of histopathological tumor regression after neoadjuvant chemotherapy in gastric adenocarcinomas:A summary of 480 cases ［J］.Annals of Surgery,2011,253(5):934-939.
［34］ SIEGEL RL,MILLER KD.Cancer statistics,2022 ［J］.CA:a Cancer Journal for Clinicians,2022,72(1):7-33.
［35］ CHEN W,ZHENG R,BAADE PD,et al.Cancer statistics in china,2015 ［J］.CA:a Cancer Journal for Clinicians,2016,66(2):115-132.
［36］ YANG L,ZHANG X,MACKAY M,et al.Identification of radioresponsive genes in esophageal cancer from longitudinal and single cell exome sequencing ［J］.International Journal of radiation Oncology Biology Physics,2020,108(4):1103-1114.
［37］ TAKAHASHI K,OSAKA Y,OTA Y,et al.Phase II study of docetaxel,cisplatin,and 5-fluorouracil chemoradiotherapy for unresectable esophageal cancer ［J］.Anticancer Research,2020,40(5):2827-2832.
［38］ LIU Y,BAO Y,YANG X,et al.Efficacy and safety of neoadjuvant immunotherapy combined with chemoradiotherapy or chemotherapy in esophageal cancer:A systematic review and meta-analysis ［J］.Frontiers in Immunology,2023,14:1117448.
［39］ YE ZM,DAI SJ,YAN FQ,et al.Dce-mri-derived volume transfer constant (k(trans)) and dwi apparent diffusion coefficient as predictive markers of short- and long-term efficacy of chemoradiotherapy in patients with esophageal cancer ［J］.Technology in Cancer Research & Treatment,2018,17:1-10.
［40］ CHEN W,WANG YT.Predictive value of early response to chemoradiotherapy in advanced esophageal squamous cell carcinoma by diffusion-weighted mr imaging ［J］.Technology in Cancer Research & Treatment,2020,19:1-7.
［41］ SUN NN,GE XL,LIU XS,et al.Histogram analysis of dce-mri for chemoradiotherapy response evaluation in locally advanced esophageal squamous cell carcinoma ［J］.La Radiologia Medica,2020,125(2):165-176.
［42］ FATIMA N,ZAMAN MU,ZAMAN A,et al.Staging and response evaluation to neo-adjuvant chemoradiation in esophageal cancers using 18fdg pet/ct with standardized protocol ［J］.Asian Pacific Journal of Cancer Prevention:APJCP,2019,20(7):2003-2008.
［43］ WANG C,ZHAO K,HU S,et al.A predictive model for treatment response in patients with locally advanced esophageal squamous cell carcinoma after concurrent chemoradiotherapy:Based on suvmean and nlr ［J］.BMC Cancer,2020,20(1):544.
［44］ SIHAG S,DE LA TORRE S,HSU M,et al.Defining low-risk lesions in early-stage esophageal adenocarcinoma ［J］.The Journal of Thoracic and Cardiovascular Surgery,2021,162(4):1272-1279.
［45］ YU Y,WEI X,CHEN X,et al.The t stage of esophageal cancer can be effectively predicted by muscularis propria thickness and muscularis propria+mucosa thickness under ultrasonic gastroscopy ［J］.Thoracic Cancer,2023,14(2):127-134.
［46］ ZHOU X,LI Y,WANG W,et al.Regulation of hippo/yap signaling and esophageal squamous carcinoma progression by an e3 ubiquitin ligase park2 ［J］.Theranostics,2020,10(21):9443-9457.
［47］ XU H,WU J,ZHANG L,et al.The measurement of nrf2 and tp53 in blood expects radiotherapeutic sensitivity in patients with esophageal cancer ［J］.Molecular and Cellular Probes,2022,66:101860.
［48］ XIA D,ZHANG XR,MA YL,et al.Nrf2 promotes esophageal squamous cell carcinoma (escc) resistance to radiotherapy through the camkiiα-associated activation of autophagy ［J］.Cell & Bioscience,2020,10(90):1-12.